Emerging Treatment Approaches for HR+/HER2– Early-Stage Breast Cancer - Episode 6
Managing CDK4/6 Inhibitor Toxicities and Encouraging Adherence
Panelists discuss how common adverse events (AEs) with CDK4/6 inhibitors in HR+/HER2- early breast cancer (eBC) vary based on treatment and patient population, with strategies for mitigating toxicities, adjusting dosing, and monitoring labs to ensure treatment continuation; they also address approaches to dose reductions, promoting treatment adherence, educating patients about toxicity management, and balancing efficacy, quality of life, and side effect risks, particularly for high-risk patients with no or low nodal involvement.
Video Player is loading.
Video content above is prompted by the following:
- What adverse events (AEs) do you commonly see in your practice with CDK4/6 inhibitors?
- In your experience, how can these vary based on the treatment and patient population?
- What strategies work best for you to mitigate these toxicities?
- What dosing adjustments or lab monitoring can help manage toxicity for treatment continuation?
- What is your approach to dose reductions or interruptions with CDK4/6 inhibitors when managing AEs? What is your threshold for dose reductions?
- How important is treatment adherence and continuation for maintaining the efficacy benefits?
- What strategies might promote adherence?
- Could you walk through your approach to educating patients about potential CDK4/6 inhibitor toxicity?
- How do you counsel patients on symptom reporting?
- How do you balance efficacy, quality of life, and adverse effect risks when selecting systemic therapy for patients with eBC?
- Does this balance shift for high-risk patients with no or low nodal involvement?
Related Content:
